PD-L1 Biomarker Testing Market Size, Share, Industry Analysis, Future Growth, Segmentation, Competitive Landscape, Trends and Forecast 2022 to 2032
The pd l1 biomarker testing market is showing a positive growth trajectory due to accelerated tracking of diseases and their associated treatment. According to new research market for PDL1 biomarker testing market, conducted by Future Market Insights (FMI), adoption of PDL1 will remain strong in the US and Europe during the course of the forecast period.
The global PD-L1
biomarker testing market is expected to be worth $597.9 million in 2022, with
demand rising at a 9.4% CAGR during the forecast period. Against this backdrop,
the market will be worth $1.46 billion by 2032.
“Market players are constantly focussing
on cost-efficient devices and strategic planning to ensure regional and
international presence. Manufacturers are also trying to direct their attention
towards improving these products,” says
the FMI Analyst.
Request a report sample to gain more market insights at @
https://www.futuremarketinsights.com/reports/sample/rep-gb-5897
Key Market Segments Covered In PD-L1 Biomarker Testing Industry Research
By Product:
·
PD-L1 22C3 Assay Kit
·
PD-L1 28-8 Assay Kit
·
PD-L1 SP142 Assay Kit
·
PD-L1 263 Assay Kit
By Indication:
·
NSCLS
·
Melanoma
·
Renal Cell Carcinoma
·
Gastrointestinal tract Malignancy
·
Haematological Malignancies
·
Ovarian Cancer
·
Other
By End User:
·
Hospitals
·
Diagnostic Laboratories
·
Cancer Research Institutes
Full
Report @ https://www.futuremarketinsights.com/reports/pd-l1-biomarker-testing-market
Comments
Post a Comment